TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives $6.00 Consensus Price Target from Brokerages

Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) have been assigned an average recommendation of “Hold” from the seven analysts that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have given a buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $6.00.

Several research firms have commented on TCRX. Needham & Company LLC reiterated a “buy” rating and issued a $6.00 price objective on shares of TScan Therapeutics in a research note on Tuesday, June 23rd. Benchmark reissued a “buy” rating on shares of TScan Therapeutics in a report on Thursday. Wedbush restated an “outperform” rating and set a $5.00 target price on shares of TScan Therapeutics in a research report on Tuesday, June 23rd. HC Wainwright reaffirmed a “buy” rating on shares of TScan Therapeutics in a report on Wednesday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of TScan Therapeutics in a research report on Friday, July 17th.

Hedge Funds Weigh In On TScan Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Landscape Capital Management L.L.C. purchased a new stake in shares of TScan Therapeutics in the 2nd quarter valued at about $25,000. Panagora Asset Management Inc. bought a new stake in shares of TScan Therapeutics during the 4th quarter valued at about $25,000. HRT Financial LP purchased a new position in shares of TScan Therapeutics during the fourth quarter worth about $26,000. Public Employees Retirement System of Ohio purchased a new position in shares of TScan Therapeutics during the first quarter worth about $28,000. Finally, Boothbay Fund Management LLC increased its position in shares of TScan Therapeutics by 50.0% in the second quarter. Boothbay Fund Management LLC now owns 24,363 shares of the company’s stock worth $35,000 after purchasing an additional 8,121 shares during the last quarter. 82.83% of the stock is currently owned by hedge funds and other institutional investors.

TScan Therapeutics Trading Up 0.9%

NASDAQ TCRX opened at $0.78 on Thursday. The company has a market cap of $50.89 million, a price-to-earnings ratio of -0.86 and a beta of 1.06. TScan Therapeutics has a 52 week low of $0.72 and a 52 week high of $2.57. The business has a 50 day moving average price of $0.90 and a 200-day moving average price of $1.01. The company has a quick ratio of 6.65, a current ratio of 3.37 and a debt-to-equity ratio of 0.31.

TScan Therapeutics (NASDAQ:TCRX) last posted its earnings results on Wednesday, August 12th. The company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.02. The company had revenue of $1.05 million for the quarter, compared to analyst estimates of $1.88 million. TScan Therapeutics had a negative net margin of 1,655.35% and a negative return on equity of 108.72%. As a group, equities analysts expect that TScan Therapeutics will post -1.12 earnings per share for the current fiscal year.

Key Headlines Impacting TScan Therapeutics

Here are the key news stories impacting TScan Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated its Buy rating on TScan Therapeutics, offering some support for the stock despite the firm’s lower earnings projections. TScan Therapeutics Earns Buy Rating from HC Wainwright
• Neutral Sentiment: Brokerage coverage overall was described as carrying a consensus rating of Hold, suggesting analysts remain cautious and that HC Wainwright’s Buy rating is not broadly shared. TScan Therapeutics Given Consensus Rating of Hold
• Negative Sentiment: HC Wainwright lowered its EPS forecasts across every year from FY2026 through FY2030: estimates were reduced to losses of $0.91, $0.89, $0.91, $0.80 and $0.16 per share, respectively. The revisions indicate the analyst expects a slower path toward profitability, despite retaining the Buy rating. Analysts Offer Insights on Healthcare Companies Including TScan Therapeutics

About TScan Therapeutics

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.